Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research

By In The News
October 1, 2021 in The Headlines

Followers 0

Reply to this topic

Recommended Posts

In The News

Posted October 1, 2021

- Share

Posted October 1, 2021

NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on...

View the full article

Quote

Link to comment

Share on other sites

Reply to this topic...

× Pasted as rich text. Paste as plain text instead

Only 75 emoji are allowed.

× Your link has been automatically embedded. Display as a link instead

× Your previous content has been restored. Clear editor

× You cannot paste images directly. Upload or insert images from URL.

Insert image from URL

Followers 0

Go to topic listing

Most Contributions
1. In The News
  201497
2. Jaydee
  13883
3. Kip Powick
  11831
4. deicer
  10839
5. dagger
  9572
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  251.4k
- Total Posts
  
  523.6k

Sign In

Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research

Recommended Posts

In The News

Link to comment

Share on other sites

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support